Stock Quote

Pfizer CEO says company to submit data on COVID-19 vaccine trial in children aged 5 to 11 within days, as U.S. daily death toll remains above 2,000

The chief executive of Pfizer Inc. said the company is expecting to submit data from late-stage trials of its COVID-19 vaccine in children ages 5 to 11 to the U.S. Food and Drug Administration within days, raising hopes that another key patient group will soon be eligible for shots.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.